BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RAD202 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RAD202\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06824155-10958@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RAD202: Phase 1 readout est. (NCT06824155)
DESCRIPTION:RAD202\, phase 1\, HER2-Positive Advanced Solid Tumors.\nStudy:
  HEAT Trial (HER2 Antibody Therapy With Lutetium-177)\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rad202#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06824155
URL:https://assetmemo.bio/drug/rad202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
